Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 25.50p 25.00p 26.00p 25.50p 25.00p 25.00p 481,216.00 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.8 -9.5 - 49.91

Motif Bio Share Discussion Threads

Showing 1101 to 1125 of 1125 messages
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older
DateSubjectAuthorDiscuss
19/2/2017
08:22
I shall go along to the Motif Bio presentation at the Rocket Bar on Tuesday. Is anyone else planning to go along? >>>>Vulgaris, could you give me a few (three ?) of what you consider the most important questions (criticisms) regarding Iclaprim to put to GL on Tuesday. TIA Did anyone see this episode of "Trust me I'm a doctor" the other week, in particular the item starting at 36:20 http://www.bbc.co.uk/iplayer/episode/b08dzvjy/trust-me-im-a-doctor-series-6-episode-2 Some researchers in the Netherlands are studing patients with Eczema associated with Staph Aureus and then attempting to reduce the Staph without hitting the other benign (beneficial bacteria). They hope to acheive this by using using endolysins (which do not cause resistance). They get the read out in around 12 months (according to the program), so I look forward to that. A quick google search comes up with quite a few hits, for example this one, which I'm guessing was written by one of the sponsors: http://www.futuremedicine.com/doi/pdf/10.2217/fmb.14.142
timbo003
01/2/2017
13:05
I have bought my first holding here today. This seems a useful informative board. The next 12 months look like they will be interesting. I am mainly in Immupharma (IMM) and there seems to be some familiar faces here too!
pdt
31/1/2017
15:59
Second RNS out 20 mins ago.
timberwolf3
31/1/2017
09:22
luminoso, agree. Excellent to get trial recruited and dosed, just they have always said they will need more cash (as they failed to raise the original amount needed on Nasdaq). Positive news today but needs to be seen in context.
waterloo01
31/1/2017
08:47
It seems clear to me that they are saying they need to raise funds to complete Revive 2 and hope that headline results from Revive 1 will allow them to do so more easily. That could be another placing or a partnership or something else. I don't read the announcement as hinting any more than that.
luminoso
31/1/2017
08:23
I suspect that last sentence hints at likely partnerships/T.O. and the possibility that a simple fundraiser may not, therefore, be required. If trials go well, this is unlikely to remain independent IMO.
small crow
31/1/2017
07:59
Really? This was from last week. Financials – the company raised $25m before expenses in its NASDAQ IPO in November 2016. We expect that in 2016 Motif will have generated an operating loss for the year of $41m with SG&A costs of $4.3m and R&D expenses of $36.8m representing the vast majority of expenses and demonstrating the sharp focus on product development within the business. We estimate that Motif will have ended 2016 with cash of $23.6m but highlight that it is likely to have ended the year with accrued trial-related costs of around $10m. In 2017 we anticipate R&D spending will decrease as the company’s REVIVE-1 and REVIVE-2 ABSSSI phase III trials complete and assuming that the third phase III trial, INSPIRE (in bacterial pneumonia), will not commence in the absence of new funding. However, we believe that the likely positive REVIVE-1 results will enable access to new funding and this will allow both the completion of REVIVE-2 and the initiation of INSPIRE (estimated to cost around $40m over 3 years).
waterloo01
31/1/2017
07:56
Above answers your question Waterloo, trial in Revive 2 ongoing, but the cash they raised last year ample funding!
bookbroker
31/1/2017
07:52
http://bit.ly/2km2rij Comment: If this last patient was treated for only 5 days there will be a further maximum of 27 days until the final follow-up phone call is completed, taking us to the end of February for the trial to be concluded. Several weeks are ordinarily required for further data processing including unblinding and statistical analysis but the company is confident of being able to report headline results in Q2. As REVIVE-2 is still ongoing, we expect only headline safety and efficacy results from REVIVE-1 will be reported (too much detail could potentially compromise the blinding of REVIVE-2). We remain confident of a positive outcome for the study based on prior efficacy and safety data obtained using iclaprim in earlier phase III trials.
ohisay
31/1/2017
07:34
A little confused as I thought they stated they needed to raise funds to complete the Revive 2 trial? Is that not now the case? They said this in November placing: While the Board believes that, along with the Company's existing cash and cash equivalents, the net proceeds of the Fundraising will provide sufficient capital to enable the Company to complete the REVIVE-1 trial, the Company will require additional funds to complete the REVIVE-2 trial and plans to raise the additional capital through public or private financings and/or other partnering opportunities.
waterloo01
31/1/2017
07:24
So . Trials completed. Will There be an anticipatory rise into results?
1savvyinvestor
31/1/2017
04:45
Appears they have completed P111 trials, and data read out will be avaliable starting 2Q 17, as per stated late 2016!
bookbroker
29/1/2017
17:04
I'd suggest a good deal higher, irrespective of the placing they have fallen considerably, a retrace of a little it would justifiable, after all they considerably strengthened the balance sheet!
bookbroker
29/1/2017
09:11
Shares in Motif Bio could rally to 35p says Zak Mir hxxp://www.proactiveinvestors.co.uk/companies/stocktube/6804/shares-in-motif-bio-could-rally-to-35p-says-zak-mir-6804.html
t-trader
26/1/2017
12:09
Interview with Zeus Capital - Dr Gary Waanders hxxp://directorstalk.com/interview-motif-bio-plc-get-updated-coverage-zeus-capital/
nilsvs
26/1/2017
09:41
Volatile today!
bookbroker
25/1/2017
09:45
Nice little rise today, I'd just love to see it do a 10/20% uplift!
bookbroker
25/1/2017
08:50
There's a bit more talk on twitter about this share
stealive
25/1/2017
07:27
yes ive seen it before.still, atleast someones got it reprinted to try and kick the price .last time it didn't seem to have any effect.maybe they thought itd work better now some of the placing stocck has gone.gl
runwaypaul
24/1/2017
17:28
htTp://www.thisismoney.co.uk/money/investing/article-4152394/SMALL-CAP-IDEAS-pharma-companies-eye-on.html Old I think but has today's date?
waterloo01
24/1/2017
06:44
MTFB closed up 4.8% on Nasdaq last night.
adorling
23/1/2017
17:14
Well done WaterlooPrefer this to summ
patviera
23/1/2017
15:58
I note Motif are presenting here. I've added of late. 12:25 Panel III – Anti Bacterial/microbiome Moderator: Sarah Haywood, CEO, MedCity Panel: • Richard Mason, Head of J&J Innovation, London, J&J • Graham Lumsden, CEO, Motif Bio • Neil Murray, CEO, Redx • Glyn Edwards, CEO, Summit htTp://cc.bingj.com/cache.aspx?q=panel+iii+%E2%80%93+anti+bacterial%2fmicrobiome+moderator%3a+sarah+haywood%2c+28th+jan+2017&d=5627567635754&mkt=en-GB&setlang=en-US&;w=QtENiXmeC83w1LQG9wWHMjeuVnO5V7Pj
waterloo01
23/1/2017
15:34
The MTFB ADS's up over 6% on Nasdaq. Beginning to look good on both sides of the Atlantic!
adorling
23/1/2017
09:49
That's a very bullish forecast from Zeus on the Voxmarket podcast Zeus risk adjusted target is now 107p/share There's another interview with Garry Waanders that appeared this morning on Directors talk: http://bit.ly/2khtnw7
timbo003
Chat Pages: 45  44  43  42  41  40  39  38  37  36  35  34  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170219 11:55:22